Pulmonary follow-up 2.5 years after a randomized, controlled, multiple dose bovine surfactant study of preterm...

Area of Science:

• Neonatology
• Pediatric Pulmonology
• Critical Care Medicine

Background:

• Respiratory distress syndrome (RDS) is a common complication in preterm infants.
• Exogenous surfactant administration is a standard treatment for RDS.
• Long-term effects of neonatal surfactant therapy on respiratory outcomes require further investigation.

Purpose of the Study:

• To evaluate the long-term effects of neonatal bovine surfactant therapy on lung function and respiratory health in preterm infants.
• To determine if early surfactant administration influences the incidence of respiratory illnesses and allergic conditions up to 2.5 years of age.

Main Methods:

• A prospective, randomized, blinded study involving 47 preterm infants.
• Infants were assigned at birth to receive either bovine surfactant or placebo.
• Lung function tests and medical history reviews were conducted at 2.5 years of age.

Main Results:

• No significant differences were observed in ventilator or oxygen therapy duration, or bronchopulmonary dysplasia incidence during initial hospitalization.
• At 2.5 years, no differences were found in growth parameters, sex ratio, or the occurrence of allergies, asthma, or other respiratory infections.
• Key lung function parameters, including functional residual capacity, tidal volume, compliance, and resistance, were similar between surfactant-treated and control groups.

Conclusions:

• Neonatal bovine surfactant therapy has minimal long-term impact on the developing respiratory system.
• Early surfactant administration neither improves nor adversely affects lung function or respiratory health in preterm infants by 2.5 years of age.